As you're about to see, Columbia Care is an especially smart way to play the U.S. marijuana stock Columbia Care ( CCHWF -4.12%). The fourth growth stock that's an amazing value during this bear market dip in the Nasdaq is U.S. Sustained double-digit growth should be the expectation for Visa shareholders. Or it could choose to organically infiltrate the Middle East, Africa, and Southeastern Asia region with its payment infrastructure over time. Since most global transactions are still being conducted in cash, Visa has the opportunity to acquire its way into potentially underbanked regions, as it did with the Visa Europe acquisition in 2016. Visa's growth runway is also exceptionally long. 31 percentage points higher than the next-closest competitor - and was the only payment processor to see significant share expansion after the Great Recession (2007-2009). As of 2020, it held 54% of credit card network purchase volume in the U.S. (the top market for consumption in the world). On a company-specific basis, Visa is the most dominant player in the U.S. If Visa shareholders are patient, they can take advantage of the natural expansion of the U.S. Even though recessions are inevitable, they don't last very long. On a macro basis, Visa and its peers benefit from the disproportionate amount of time the U.S. Having so much capital on hand has allowed the company to reignite its internal research engine, and fund numerous drug-development partnerships. It ended March with approximately $2 billion in cash, cash equivalents, and restricted cash equivalents and investments. What's more, Exelixis is swimming with cash. But with somewhere in the neighborhood of six dozen clinical studies ongoing to assess Cabometyx as a monotherapy or combination therapy in an assortment of cancer types, label expansion is a very real possibility. These indications alone offer more than $1 billion in annual sales potential. Cabometyx is approved to treat first- and second-line renal cell carcinoma, as well as advanced hepatocellular carcinoma that's previously been treated. What makes this cancer-drug developer so special is its blockbuster drug Cabometyx. This puts a pretty safe floor beneath drug stocks like Exelixis. economy or stock market perform, or how high inflation flies, patients will continue to need prescription drugs, medical devices, and healthcare services. If there's one great thing about healthcare stocks, it's that they're defensive. For Nio, the benefit is high-margin monthly subscription revenue and the loyalty of early buyers.
#NAMELY STOCK UPGRADE#
With BaaS, buyers receive a discount off the purchase price of their EV, and can charge, swap, and upgrade their batteries at a later date.
There's also Nio's battery-as-a-service (BaaS) subscription, which it introduced in August 2020. The ET7 sedan, which began deliveries in late March, and the ET5 sedan, which is expected to be delivered to customers in September, can travel 621 miles on a single charge with the top battery upgrade. Nio has regularly introduced new vehicles to its lineup to broaden its appeal to domestic EV buyers. Investors should also appreciate the company's innovation, which can be seen on multiple fronts. Once part availability improves, little will stand in the way of Nio's expansion.
Prior to the pandemic throwing a monkey wrench into domestic supply chains, Nio's management team believed it would hit an annual run-rate of 600,000 EVs (50,000 EVs/month) by the end of the year. In June and July, Nio delivered 12,961 EVs and 10,052 EVs, respectively. We've already been given a brief glimpse of the company's ability to ramp its production. Although auto stocks are contending with a flurry of semiconductor chip and parts shortages tied to the COVID-19 pandemic, these are short-term concerns that don't alter Nio's long-term growth trajectory. The first phenomenal growth stock you'll be kicking yourself over if you don't scoop it up on the Nasdaq bear market decline is China-based electric vehicle (EV) manufacturer Nio ( NIO 13.52%).
What follows are five fantastic growth stocks you'll regret not buying during the current Nasdaq bear market dip. indexes, including the growth-driven Nasdaq Composite, are opportunities for long-term investors to pounce.Īt the moment, growth stocks offer some of the most attractive valuations on Wall Street. This means all sizable declines in the major U.S. Namely, every bear market decline and stock market correction throughout history has eventually been wiped away by a bull market rally. But there's an interesting fact about bear markets that all patient investors should know.
0 kommentar(er)
